196 results on '"Harris, John E"'
Search Results
2. Multispecies-targeting siRNAs for the modulation of JAK1 in the skin
3. 501 - Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo
4. 519 - Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months
5. Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine ligand-receptor pairs that drive disease
6. Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin
7. Lesional CD8+ T-Cell Number Predicts Surgical Outcomes of Melanocyte–Keratinocyte Transplantation Surgery for Vitiligo
8. Expanding the White Armor of Vitiligo
9. Vitiligo Progression in a Patient Undergoing Romosozumab Treatment for Osteoporosis
10. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm
11. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendations
12. Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients With Vitiligo Who Significantly Repigment Following Treatment With Ruxolitinib Cream
13. Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo
14. Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort
15. Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study
16. Assessing risk amid uncertainty inside and outside the dermatology clinic
17. Vitiligo Induced by Dupilumab Treatment: A Case Series
18. Adolescent extra‐truncal progressive macular hypomelanosis
19. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
20. Narrowband ultraviolet B phototherapy in pediatric vitiligo: A retrospective study
21. Pathogenesis of Vitiligo
22. Activation of the NLRP1 inflammasome in human keratinocytes by the dsDNA mimetic poly(dA:dT)
23. Effect of ruxolitinib cream on achievement of VASI50 by body region: Week 52 pooled analysis of the TRuE-V phase 3 studies
24. CXCL9 links skin inflammation and fibrosis via CXCR3-dependent upregulation of collagen 1a1 in fibroblasts
25. Addition of Narrow-Band UVB Phototherapy to Ruxolitinib Cream in Patients With Vitiligo
26. A Keratinocyte-Tethered Biologic Enables Location-Precise Treatment in Mouse Vitiligo
27. Regulatory T Cells Require CCR6 for Skin Migration and Local Suppression of Vitiligo
28. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
29. Vitiligo of the arm after COVID-19 vaccination
30. 34631 Do patients with vitiligo and health care professionals treating them recognize the burden in living with the disease in the United States? Findings from the VALIANT study
31. 34612 Exploring the natural history of vitiligo in the United States: Findings from the VALIANT study
32. RNAi-based modulation of IFN-γ signaling in skin
33. Vitiligo
34. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial
35. Keratinocyte-tethering modification for biologics enables location-precise treatment in mouse vitiligo
36. Systemic therapies in vitiligo: a review
37. Immunology of the Skin
38. Gene Expression Profiling in the Skin Reveals Strong Similarities between Subacute and Chronic Cutaneous Lupus that Are Distinct from Lupus Nephritis
39. scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in T reg function
40. 27568 Maintenance of repigmentation after discontinuation of ruxolitinib cream in patients with vitiligo
41. 27535 Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: 104-week data from a phase 2 study
42. 27636 Addition of narrow-band ultraviolet light B phototherapy to ruxolitinib cream in patients with vitiligo
43. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma
44. Editorial: Immunology of Vitiligo
45. Treatment recommendations for patients with vitiligo during COVID‐19
46. Resident Memory T Cells in Autoimmune Skin Diseases
47. Gaining Insight into Vitiligo Genetics through the Lens of a Large Epidemiologic Study
48. Translational Research in Vitiligo
49. Jak Inhibitors Reverse Vitiligo in Mice but Do Not Deplete Skin Resident Memory T Cells
50. 17753 Analysis of 24-week response to ruxolitinib cream for the treatment of vitiligo based on patient demographics and clinical characteristics
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.